Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune is headquartered in the UK, with a discovery research centre in Dortmund, Germany and an office in Cambridge MA, USA.
External link for Oncimmune
1 Park Row
Leeds, Yorkshire LS1 5AB, GB
Otto-Hahn Straße. 15
Dortmund, 44227, DE
One Broadway
14th Floor
Cambridge, MA 02142, US
Musings on this year’s #BIOEurope
Just had an idle thought concerning this year’s #BIOEurope conference. I wonder how many meetings/deals were done in the queue for the Novartis coffee machine? I suspect many! A thoroughly enjoyable event as ever and also a productive one for Oncimmune! Now recovering ahead of our GM tomorrow!
Profiling IgE autoantibodies represents a significant advancement due to several challenges associated with IgE detection. Unlike other #immunoglobulins like IgG, which are present in much higher concentrations, #IgE is often found at a ratio of 1 to 1 million compared to IgG. This low concentration makes it difficult to identify specific antigens that IgE binds to. #Oncimmune #AutoantibodyProfiling
Following a successful trading update, our CEO, Martin Gouldstone speaks to Proactive about securing three new contracts, the strengthening of the company’s revenue pipeline, and commercial momentum. Listen to the whole interview here: https://lnkd.in/d3hhJEPZ #companyupdate #Oncimmune
Hello from Stockholm! Our CEO Martin Gouldstone and VP and Head of Sales Mike Fisher PhD are at #bioeurope2024! Interested in meeting up and finding out how #autoimmunity profiling can help you research? Reach out to them directly!
We’re proud to see our strategic focus and efforts paying off following our recent fundraise and debt recapitalisation. In the last three months alone, we’ve signed eight new contracts valued at a total of £2.14m, with three recent agreements contributing £0.34m. This sustained commercial momentum positions us on track for a profitable 2025. Read more: https://lnkd.in/dFvB2PJY #Oncimmune #TradingUpdate #HealthcareInnovation #Immunology #Growth
We’re excited to be attending the Society for Immunotherapy of Cancer (SITC) conference in Houston, TX, from November 6-10! Our Biopharma Partnerships Manager, Elena Chavez, will be there, to connect with fellow innovators in immunotherapy. At Oncimmune, antibody biomarkers are at the core of our mission to advance disease characterization, identify therapeutic targets, predict clinical responses, and drive personalized treatment strategies. If you're attending #SITC2024 and want to explore opportunities in biomarker-driven science, reach out to Elena to schedule a meeting. #Oncimmune #Biomarkers #Immunotherapy #ScientificInnovation
We are pleased to share our latest trading update, reflecting recent advancements and financial highlights. "Following the fundraise, and successful debt recapitalisation of the business announced on the 18 October 2024, I am pleased to see that our relentless focus on the commercial side of the business continues to bear fruit..." Martin Gouldstone, CEO Read the full update here: https://lnkd.in/dFvB2PJY #CompanyUpdate #FinancialHighlights
Our very own Chief Scientific Officer, Petra Budde will be presenting at this year's xMap CONNECT event by Luminex. Petra will discuss "Enabling Autoantibody Quantification through Xmap Multiplexing Technology". Join us on the 12th November at 12.00P PM at the KIT - Royal Tropical Institute, Amsterdam if you are interested in finding out more about cutting-edge advancements in autoantibody profiling. #Oncimmune #AutoantibodyProfiling #ScientificAdvancement
Are you attending this year's #BIOEurope in Stockholm, Sweden, November 4–6? Oncimmune's CEO, Martin Gouldstone, and VP, Head of Business Development, Mike Fisher PhD, will be there and looking forward to engaging with fellow professionals in the life sciences sector. They are eager to discuss autoantibody profiling and explore how it can enhance your research efforts. If you're interested in learning more or would like to schedule a meeting, reach out to them directly! Let's connect and drive innovation together. #Networking #LifeSciences #AutoantibodyProfiling
At Oncimmune, we are at the forefront of cutting-edge autoantibody profiling that has the potential to reshape #DrugDevelopment and research across immunology, #oncology, and autoimmune diseases. IgE, long associated with allergic conditions, is now being increasingly linked to autoimmune diseases such as #lupus and certain types of #cancer. Our newly developed assay offers unprecedented sensitivity, allowing for reliable and precise IgE profiling—a significant advancement for both research and therapeutic discovery. Below is an exclusive Q&A with our Chief Scientific Officer, Petra Budde, where she delves into the scientific importance of IgE profiling. Interested in finding out more? Email us at info@onimmune.com to book a meeting with a member of our team.